Based in Boston, Massachusetts, Motus Therapeutics is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Their lead product candidate, relamorelin, is a ghrelin agonist used to treat diabetic gastroparesis and other GI functional disorders. The company was previously known as Rhythm Health and is backed by investors such as MPM Capital and New Enterprise Associates. Motus Therapeutics was previously a subsidiary of Rhythm Holding Company.